Rheumatoid arthritis

First oral JAK gets PBS


The oral therapy tofacitinib citrate (Xeljanz) has gained a PBS listing for the treatment of moderate to severe rheumatoid arthritis.

It is the first Janus kinase (JAK) inhibitor to be given the greenlight by the PBS and will be reimbursed from 1st October.

At a recommended dosage of 5mg twice daily, Pfizer’s Xeljanz can be used alone or in combination with non-biological DMARDs, including methotrexate.

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic